PROTEA BIOPHARMA NV: what changed
What changed
PROTEA BIOPHARMA NV
NACE 72.101, Research and development on biotechnology
filed annual accounts (NBB)
Net result for the year
-€44,940
2022 · -€244,094+€199,154
Equity
-€999,054
2022 · -€954,114-€44,940
Cash
€3,072
2022 · €3,701-€629
Balance sheet total
€1.3m
2022 · €1.3m+€16,194
Largest movements
Assets
- Receivables within one year +€19,563
up €19,563 (+45.6%), from €42,928 to €62,491
of which Trade receivables: +€10,000
Equity and liabilities
- Debts after one year +€52,000
up €52,000 (+2.4%), from €2.2m to €2.2m
- Profit (loss) carried forward -€44,940
down €44,940 (-4.0%), from -€1.1m to -€1.2m
- Tax, wage and social debts +€34,249
new in 2023: €34,249
- Trade debts -€25,116
down €25,116 (-56.7%), from €44,320 to €19,204
Income statement
- Gross operating margin +€131,360
up €131,360 (+75.8%), from -€173,200 to -€41,839
- Depreciation -€67,937
down €67,937 (-97.2%), from €69,873 to €1,936
Change in the result, 2022 to 2023
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Result 2022
-€244,094
Gross operating margin
+€131,360
Depreciation
+€67,937
Other operating charges
-€92
Financial income
-€1
Financial charges
-€50
Result 2023
-€44,940
raises the resultlowers the result
Derived cash bridge
The bridge is derived from the 2022 and 2023 balance sheets and the 2023 result. There is no filed cash-flow statement. You see where the money came from and where it went.
From operations
-€52,629
Investment
€0
Financing
+€52,000
Cash 2022
€3,701
From operations (derived)
-€52,629
Net result for the year
-€44,940
Depreciation
+€1,936
Receivables within one year
-€19,563
Deferred charges and accrued income
+€805
Trade debts
-€25,116
Tax, wage and social debts
+€34,249
Financing
+€52,000
Debts after one year
+€52,000
Cash 2023
€3,072
brings cash intakes cash out
Every line side by side
| Line | Code | 2022 | 2023 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €1,283,752 | €1,299,945 | +€16,194 | +1.3% |
| Fixed assets | 21/28 | €1,236,318 | €1,234,382 | -€1,936 | -0.2% |
| Tangible fixed assets | 22/27 | €5,034 | €3,099 | -€1,936 | -38.5% |
| Plant, machinery and equipment | 23 | €1,463 | €975 | -€488 | -33.3% |
| Furniture and vehicles | 24 | €502 | €295 | -€207 | -41.3% |
| Other tangible fixed assets | 26 | €3,069 | €1,829 | -€1,241 | -40.4% |
| Financial fixed assets | 28 | €1,231,284 | €1,231,284 | = | 0.0% |
| Current assets | 29/58 | €47,434 | €65,563 | +€18,129 | +38.2% |
| Amounts receivable within one year | 40/41 | €42,928 | €62,491 | +€19,563 | +45.6% |
| Trade receivables | 40 | €6,868 | €16,868 | +€10,000 | +146% |
| Other amounts receivable | 41 | €36,060 | €45,623 | +€9,563 | +26.5% |
| Cash at bank and in hand | 54/58 | €3,701 | €3,072 | -€629 | -17.0% |
| Deferred charges and accrued income | 490/1 | €805 | - | -€805 | |
| Total equity and liabilities | 10/49 | €1,283,752 | €1,299,945 | +€16,194 | +1.3% |
| Equity | 10/15 | -€954,114 | -€999,054 | -€44,940 | -4.7% |
| Contributions | 10/11 | €170,000 | €170,000 | = | 0.0% |
| Capital | 10 | €170,000 | €170,000 | = | 0.0% |
| Issued capital | 100 | €170,000 | €170,000 | = | 0.0% |
| Reserves | 13 | €576 | €576 | = | 0.0% |
| Non-distributable reserves | 130/1 | €576 | €576 | = | 0.0% |
| Reserves not available under the articles | 1311 | €576 | €576 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€1,124,690 | -€1,169,630 | -€44,940 | -4.0% |
| Amounts payable | 17/49 | €2,237,865 | €2,298,999 | +€61,133 | +2.7% |
| Amounts payable after more than one year | 17 | €2,191,671 | €2,243,671 | +€52,000 | +2.4% |
| Financial debts | 170/4 | €2,191,671 | €2,243,671 | +€52,000 | +2.4% |
| Amounts payable within one year | 42/48 | €44,320 | €53,454 | +€9,133 | +20.6% |
| Trade debts | 44 | €44,320 | €19,204 | -€25,116 | -56.7% |
| Suppliers | 440/4 | €44,320 | €19,204 | -€25,116 | -56.7% |
| Taxes, remuneration and social security | 45 | - | €34,249 | +€34,249 | |
| Taxes | 450/3 | - | €34,249 | +€34,249 | |
| Accrued charges and deferred income | 492/3 | €1,875 | €1,875 | = | 0.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €69,873 | €1,936 | -€67,937 | -97.2% |
| Other operating charges | 640/8 | €868 | €960 | +€92 | +10.6% |
| Gross operating margin | 9900 | -€173,200 | -€41,839 | +€131,360 | +75.8% |
| Operating profit (loss) | 9901 | -€243,940 | -€44,735 | +€199,205 | +81.7% |
| Financial income | 75/76B | €1 | - | -€1 | |
| Recurring financial income | 75 | €1 | - | -€1 | |
| Financial charges | 65/66B | €154 | €205 | +€50 | +32.4% |
| Recurring financial charges | 65 | €154 | €205 | +€50 | +32.4% |
| Profit (loss) for the period before taxes | 9903 | -€244,094 | -€44,940 | +€199,154 | +81.6% |
| Profit (loss) for the period | 9904 | -€244,094 | -€44,940 | +€199,154 | +81.6% |
| Profit (loss) for the period to be appropriated | 9905 | -€244,094 | -€44,940 | +€199,154 | +81.6% |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Compare this company with its sector.Sector benchmark
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2022 and 31 December 2023. Green is a favourable move for that line, red an unfavourable one. Prepared on 7 November 2026 via checked.be.